NCT01061385已完成不适用
IDE G090121 A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Intragastric Balloon (RIBTM) in Obese Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- %Excess Weight Loss
研究概览
简要总结
The study evaluated the safety and efficacy of the ReShape Intragastric Balloon as an adjunct to diet and exercise in obese patients compared with diet and exercise alone. The study device is designed to occupy space within the stomach and induce satiety. After approval from the institutional review board, patients provided written consent and were randomized to the treatment group (with endoscopic placement of study device) or the control group (no placement of study device) on an unblinded basis. Both groups received similar diet and exercise counseling. After 24 weeks, the device was removed. Patient weight, adverse events, and quality of life data were evaluated throughout the 48 week study duration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged ≥ 20 years and ≤ 60 years;
- •At screening, body mass index (BMI) ≥ 30 Kg/m^2 and ≤ 40 Kg/m^2;
- •Have a history of obesity (BMI ≥ 30 kg/m^2) for at least 6 months and have failed other weight-reduction alternatives, such as supervised diet, exercise and behavioral modification programs;
- •Subject is willing to commit to a long-term low calorie (1000-1500 calories/day) supervised diet;
- •Subject has reasonable weight loss expectations (accept a goal of losing up to 15% of body weight after 24 weeks);
- •At screening, total Beck Depression Inventory (BDI) score < 12 points, and BDI affective subscale score < 7 points.
- •Subject is able to follow requirements outlined in the protocol, including complying with the visit schedule, and willing to undergo protocol-specific procedures, e.g., endoscopy, local sedation, general anesthesia, electrocardiography (ECG), and/or clinical laboratory testing;
- •Subject is willing to take prescribed proton pump inhibitors (PPIs);
- •Subject is able to provide written informed consent;
- •If female of child-bearing potential, the subject is willing to use contraception (e.g., birth control pills, condoms, abstinence) and avoid pregnancy during the study.
排除标准
- •Participating in an organized weight loss program (e.g., Weight Watchers);
- •Parkinson's disease;
- •Chronic narcotic use;
- •Clinically relevant abdominal adhesions (e.g., history of bowel obstruction);
- •History or symptoms of gastrointestinal (GI) surgery (excluding uncomplicated appendectomy and cholecystectomy), obstruction, and/or adhesive peritonitis;
- •History or symptoms of clinically significant esophageal or GI motility disorders;
- •A hormonal or genetic cause for subject's obesity;
- •A history of myocardial infarction in the previous 6 months, current New York Heart Association (NYHA) Functional Class III or IV (heart failure) or cardiac arrhythmia (e.g., atrial fibrillation);
- •History or symptoms of varices, bowel obstruction, congenital or acquired GI anomalies (e.g., atresias, stenosis, stricture, and/or diverticula), severe renal, hepatic, and/or pulmonary disease;
- •History or symptoms of inflammatory bowel disease, such as Crohn's disease;
- •History or symptoms of uncontrolled or unstable thyroid disease;
- •Subjects with a positive breath test for Helicobacter pylori at screening;
- •History or symptoms in the past 12 months of significant irritable bowel disease, peritonitis, active esophagitis, gastric or duodenal ulceration, or GI bleeding;
- •History of esophageal and/or stomach cancer.
- •Type I diabetes;
- •Placement of previous intragastric balloon or similar device with associated adverse; or any endogastric procedure within the last 6 months;
- •Ongoing treatment with anticoagulants, steroids, aspirin (> 81 mg/day), non-steroidal anti-inflammatory drugs (NSAIDS), or other medications known to be gastric irritants or to reduce GI motility, and unwillingness to discontinue the use of these concomitant medications;
- •Concomitant use of prescription, non-prescription, or over-the-counter weight loss medications or supplements at any time during the study;
- •Evidence of untreated psychiatric or eating disorders, such as major depression, schizophrenia, substance abuse, binge eating disorder, or bulimia;
- •Pregnancy, breast feeding, or intention of becoming pregnant during the study (if female of childbearing potential);
- •Known allergy to silicone;
- •A history of anemia
- •Participation in another investigational trial within 1 month of screening or planned enrollment during the study period.
- •Presence of peptic ulcerations, hiatal hernia (> 2 cm), patulous pyloric channel, erosive esophagitis, varices, angiectasia, Barrett's esophagus or other findings deemed exclusionary in the opinion of the investigator.
结局指标
主要结局
%Excess Weight Loss
时间窗: 36 Weeks
the difference between the %EWL between treatment and control groups must be clinically significant
次要结局
- Percentage of Subjects With >=25% Excess Weight Loss (EWL)(12 months)
研究者
相似试验
已完成
不适用
ReShape Intragastric Balloon for the Treatment of ObesityObesityNCT01024465ReShape Lifesciences26
进行中（未招募）
不适用
Effectiveness of Intragastric balloon associated with diet on treatment of patients with type 2 diabetesutritional and metabolic diseasesObesityDiabetes Mellitus, Type 2C18.654.726.500C18.452.394.750.149RBR-3ypfxvFaculdade de Medicina da Univesidade de São Paulo
尚未招募
不适用
Effectiveness Gastric Balloon in Obese AdolescentsObesity, MorbidNCT04209842Stanford University20
终止
不适用
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist CandidatesObesityLiver CirrhosisNCT02556138Mayo Clinic8
尚未招募
2 期
Efficacy of BioEnterics Intragastric Balloon System for the treatment of morbid obesityMorbid obesityJPRN-UMIN000005521Division of Gastroenterology and Hepatology, University of Tsukuba Hospital12